Title
Description description description. Description description description. Description description description.
As a parent, you have to speak up for your child. That means talking to the doctor about why TASIGNA® (nilotinib) capsules may be the right option to treat your child’s Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
Your child’s doctor will determine the proper dose of TASIGNA based on your child’s body weight and height.
In a clinical study of 25 children whose first treatment for Ph+ CML-CP was TASIGNA.
6 out of 10 children (15 of 25 patients) achieved a major molecular response (MMR) at 12 cycles (28 days per cycle or 336 days, so under 1 year).
In a clinical study of 44 children who couldn’t tolerate or no longer benefited from GLEEVEC® (imatinib mesylate) or dasatinib who were switched to TASIGNA.
4 out of 10 children (18 of 44 patients) achieved an MMR at 12 cycles (28 days per cycle or 336 days, so under 1 year).
Whether your child has been recently diagnosed with Ph+ CML-CP or is currently taking another medication to treat the disease, make yourself heard—and speak with your child’s doctor about TASIGNA.
In clinical trials with TASIGNA, the most common side effects in children included:
Be sure to review information about the serious and most common side effects of TASIGNA. Learn more
Use of website is governed by the Terms of Use and Privacy Policy.
Copyright © 2020 Novartis Pharmaceuticals Corporation. All rights reserved.
You are now leaving the Novartis site and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel or click OK to continue.
